.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,503,497

« Back to Dashboard

Claims for Patent: 6,503,497

Title: Use of borate-polyol complexes in ophthalmic compositions
Abstract:Water-soluble borate-polyol complexes are useful as buffers and/or antimicrobials in aqueous ophthalmic compositions, including those containing polyvinyl alcohol. These compositions have greater antimicrobial activity than comparable compositions containing typical borate buffers and unexpectedly increase the antimicrobial efficacy of other antimicrobial agents when used in combination. In addition, use of the boratepolyol complexes avoids the incompatibility problem typically associated with the combination of borate buffer and polyvinyl alcohol; therefore, the compositions disclosed herein may also contain polyvinyl alcohol.
Inventor(s): Chowhan; Masood (Arlington, TX), Dassanayake; Nissanke L. (Arlington, TX)
Assignee: Alcon Manufacturing, Ltd. (Fort Worth, TX)
Application Number:10/027,998
Patent Claims: 1. An aqueous ophthalmic composition comprising: 0.5 to 6.0 wt. % of a water soluble borate-polyol complex to enhance the antimicrobial activity of the composition, and water, said complex containing borate and polyol in a molar ratio of 1:0.1 to 1:10.

2. An aqueous ophthalmic composition according to claim 1, wherein the borate-polyol complex comprises a borate selected from the group consisting of boric acid, sodium borate, potassium borate, calcium borate, magnesium borate and manganese borate.

3. An aqueous ophthalmic composition according to claim 1, wherein the polyol is selected from the group consisting of mannitol, glycerin, propylene glycol and sorbitol.

4. An aqueous ophthalmic composition according to claim 3, wherein the polyol comprises mannitol.

5. An aqueous ophthalmic composition according to claim 3, wherein the polyol comprises glycerin.

6. An aqueous ophthalmic composition according to claim 3, wherein the polyol comprises propylene glycol.

7. An aqueous ophthalmic composition according to claim 3, wherein the polyol comprises sorbitol.

8. An aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the borate-polyol complex is included in the composition at a concentration of 1.0 to 2.5 wt. %.

9. An aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the molar ratio of borate to polyol is 1:0.25 to 1:2.5.

10. An aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the molar ratio of borate to polyol is 1:0.1 to 1:1.

11. An aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the molar ratio of borate to polyol is 1:0.25 to 1:0.75.

12. An aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the borate-polyol complex is included in the composition at a concentration of 1.0 to 2.5 wt. %, and the molar ratio of borate to polyol is 1:0.25 to 1:2.5.

13. An aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the borate-polyol complex comprises boric acid.

14. An aqueous ophthalmic composition according to claim 13, wherein the borate-polyol complex is included in the composition at a concentration of 1.0 to 2.5 wt. %, and the molar ratio of borate to polyol is 1:0.1 to 1:1.

15. An aqueous ophthalmic composition according to any one of the claims 1 to 7, wherein the borate-polyol complex comprises boric acid and sodium borate.

16. An aqueous ophthalmic composition according to claim 15, wherein the borate-polyol complex is included in the composition at a concentration of 1.0 to 2.5 wt. %, and the molar ratio of borate to polyol is 1:0.1 to 1:1.

17. An aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the composition further comprises a preservative effective amount of an ophthalmically acceptable antimicrobial agent.

18. An aqueous ophthalmic composition according to claim 17, wherein the antimicrobial agent comprises polyquaternium-1.

19. An aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the composition does not contain an ophthalmically acceptable antimicrobial agent.

20. An aqueous ophthalmic composition according to claim 8, wherein the composition is unpreserved.

21. An aqueous, unpreserved ophthalmic solution comprising an amount of a water soluble borate-polyol complex effective to enhance the antimicrobial activity of the solution.

22. An aqueous ophthalmic solution comprising: 0.5 to 6.0 wt. % of a water soluble borate-polyol complex to enhance the antimicrobial activity of the solution, and water, said borate-polyol complex comprising borate and glycerin in a molar ratio of 1:0.1 to 1:10.

23. An aqueous ophthalmic solution according to claim 22, wherein the solution further comprises an effective amount of a viscosity enhancing polymer.

24. An aqueous ophthalmic solution according to claim 23, wherein the viscosity-enhancing polymer comprises a cellulosic polymer.

25. An aqueous ophthalmic solution according to claim 24, wherein the cellulosic polymer comprises hydroxypropyl methylcellulose.

26. An aqueous ophthalmic solution according to any one of claims 22 to 25, wherein the solution further comprises a preservative effective amount of an ophthalmically acceptable antimicrobial agent.

27. An aqueous ophthalmic solution according to claim 26, wherein the ophthalmically acceptable antimicrobial agent comprises polyquaternium-1.

28. An aqueous ophthalmic solution according to any one of claims 22 to 25, wherein the solution does not contain an ophthalmically acceptable antimicrobial agent.

29. An aqueous ophthalmic solution according to any one of claims 22 to 25, wherein the solution contains the borate-polyol complex in an amount of 1.0 to 2.5 wt. %.

30. An aqueous ophthalmic solution according to claim 29, wherein the molar ratio of borate to polyol is 1:0.1 to 1:1.

31. An aqueous ophthalmic solution according to claim 29, wherein the molar ratio of borate to polyol is 1:0.25 to 1:2.5.

32. An aqueous ophthalmic solution according to claim 29, wherein the solution is unpreserved.

33. An aqueous ophthalmic solution comprising: 0.5 to 6.0 wt. % of a water soluble borate-polyol complex to enhance the antimicrobial activity of the solution, and water, wherein the borate-polyol complex comprises borate, propylene glycol and sorbitol and the molar ratio of borate to polyol is 1:0.1 to 1:10.

34. An aqueous ophthalmic solution according to claim 33, wherein the solution further comprises an effective amount of a viscosity-enhancing polymer.

35. An aqueous ophthalmic solution according to claim 34, wherein the viscosity-enhancing polymer comprises a cellulosic polymer.

36. An aqueous ophthalmic solution according to claim 35, wherein the cellulosic polymer comprises hydroxypropyl methylcellulose.

37. An aqueous ophthalmic solution according to any of claims 33 to 36, wherein the solution further comprises a preservative effective amount of an ophthalmically acceptable antimicrobial agent.

38. An aqueous ophthalmic solution according to claim 37, wherein the ophthalmically acceptable antimicrobial agent comprises polyquaternium-1.

39. An aqueous ophthalmic solution according to any one of claims 33 to 36, wherein the solution does not contain an ophthalmically acceptable antimicrobial agent.

40. An aqueous ophthalmic solution according to any one of claims 33 to 36, wherein the solution contains the borate-polyol complex in an amount of 1.0 to 2.5 wt. %.

41. An aqueous ophthalmic solution according to claim 40, wherein the molar ratio of borate to polyol is 1:0.1 to 1:1.

42. An aqueous ophthalmic composition according to claim 40, wherein the molar ratio of borate to polyol is 1:0.25 to 1:2.5.

43. An aqueous ophthalmic solution according to claim 40, wherein the solution is unpreserved.

44. An aqueous ophthalmic solution comprising: a viscosity-enhancing amount of hydroxypropyl methylcellulose; 1.0 to 2.5 wt. % of a borate-polyol complex, said complex comprising boric acid and glycerin in a molar ratio of 1:0.1 to 1:1; 0.001 w/v % of polyquaternium-1; and water.

45. An aqueous, unpreserved ophthalmic solution comprising: a viscosity-enhancing effective amount of hydroxypropyl methylcellulose; 1.0 to 2.5 wt. % of a borate-polyol complex comprising boric acid, propylene glycol and sorbitol, wherein the molar ratio of borate to polyol is 1:0.1 to 1:1; and water.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc